- Alfred Lagaya
The Therapeutic Antibody Revolution in the Post Genomics Era - Carterra and Twist Bioscience
Updated: Apr 12, 2021
The first segment of the talk will be presented by Noah Ditto, Technical Product Manager at Carterra. He will demonstrate how modern-day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This new paradigm combines screening and detailed characterization in the same step, condensing months of work into days.
The second part of the event will be led by Aaron Sato (Cheif Scientific Office of Biopharma at Twist Biosciences), showing how their antibody engineering platform has revamped the discovery workflow to take advantage of the ongoing revolution in synthetic biology. In six weeks, we designed, produced, and screened a new antibody library and identified high affinity antibodies that target the S1 spike protein of SARS-CoV-2, as well as to the human ACE2 cellular receptor to which SARS-CoV-2 mediates viral entry. Crucially, the high throughput and low reagent use of the Carterra LSA platform has allowed us to take full advantage of our antibody expression and purification workflow to characterize hundreds of the lead candidates by affinity, specificity, and epitope bin.